MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines

by Arriola, E, Cañadas, I, Arumí-Uría, M, Dómine, M, Lopez-Vilariño, J A, Arpí, O, Salido, M, Menéndez, S, Grande, E, Hirsch, F R, Serrano, S, Bellosillo, B, Rojo, F, Rovira, A, Albanell, J
Published 2011

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

by Alba, E, Albanell, J, de la Haba, J, Barnadas, A, Calvo, L, Sánchez-Rovira, P, Ramos, M, Rojo, F, Burgués, O, Carrasco, E, Caballero, R, Porras, I, Tibau, A, Cámara, M C, Lluch, A
Published 2014

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

by Prat, A, Lluch, A, Albanell, J, Barry, W T, Fan, C, Chacón, J I, Parker, J S, Calvo, L, Plazaola, A, Arcusa, A, Seguí-Palmer, M A, Burgues, O, Ribelles, N, Rodriguez-Lescure, A, Guerrero, A, Ruiz-Borrego, M, Munarriz, B, López, J A, Adamo, B, Cheang, M C U, Li, Y, Hu, Z, Gulley, M L, Vidal, M J, Pitcher, B N, Liu, M C, Citron, M L, Ellis, M J, Mardis, E, Vickery, T, Hudis, C A, Winer, E P, Carey, L A, Caballero, R, Carrasco, E, Martín, M, Perou, C M, Alba, E
Published 2014